Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-06-19
2007-06-19
Shibuya, Mark L. (Department: 1639)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S011400
Reexamination Certificate
active
10292732
ABSTRACT:
The invention relates to the use of cyclic Prolyl Glycine (“cyclic PG” or “cPG”) and analogs and mimetics thereof, as neuroprotective agents for the treatment and or prevention of neurological disorders including but not limited to cerebral ischemia or cerebral infarction resulting from a range of phenomena, such as thromboembolic or hemorrhagic stroke, cerebral basospasms, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia such as from drowning, pulmonary surgery, and cerebral trauma, as well as to the treatment and prevention of chronic neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, and as anticonvulsants.
REFERENCES:
patent: 5439930 (1995-08-01), Seredenin et al.
patent: 6124361 (2000-09-01), Chenard
patent: 6187906 (2001-02-01), Gluckman et al.
patent: 6251865 (2001-06-01), Clark
patent: 6258582 (2001-07-01), Acton
patent: 6284778 (2001-09-01), Zelle
patent: 6291213 (2001-09-01), Rothstein
patent: 6291511 (2001-09-01), Durette
patent: 6303576 (2001-10-01), Blaschuk et al.
patent: 6689904 (2004-02-01), Greenfield et al.
patent: 2003/0109531 (2003-06-01), Tran
patent: 0366638 (1990-02-01), None
patent: 0363994 (1990-04-01), None
patent: 515371 (2001-11-01), None
patent: 515432 (2001-11-01), None
patent: WO 9302695 (1993-02-01), None
patent: WO99/47490 (1999-09-01), None
patent: 03/039487 (2003-05-01), None
patent: 03/039487 (2003-05-01), None
patent: 03/041655 (2003-05-01), None
Gangemi et al., Regulatory genes controlling cell fate choice in embryonic and adult neural stem cells, Journal of Neurochemistry, 2004, vol. 89, pp. 286-306.
Liu et al., cAMP, tubulin, axonal transport and generation, Experimental Neurology, vol. 189, (2004), pp. 199-203.
Bhargava et al., Neuropharmacology, vol. 21, pp. 917-922, 1982.
Gudasheva et al., European Journal of Drug Metabolism and Pharmacokinetics 1997, vol. 22, No. 3, pp. 245-252.
David R. Preston & Associates APC
Preston David
Shibuya Mark L.
LandOfFree
Neuroprotection and neuroegenisis by administering cyclic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neuroprotection and neuroegenisis by administering cyclic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neuroprotection and neuroegenisis by administering cyclic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3873244